Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,892
  • Shares Outstanding, K 22,900
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -10,260 K
  • 36-Month Beta 0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.96 +52.08%
on 05/24/18
1.76 -17.05%
on 05/25/18
+0.47 (+46.73%)
since 05/18/18
3-Month
0.81 +80.25%
on 04/23/18
1.76 -17.05%
on 05/25/18
+0.21 (+16.80%)
since 03/19/18
52-Week
0.69 +111.59%
on 11/29/17
2.65 -44.91%
on 12/07/17
-0.45 (-23.56%)
since 06/19/17

Most Recent Stories

More News
VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101

VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders, today...

VTGN : 1.46 (-1.35%)
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders

Patent Covers Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells

VTGN : 1.46 (-1.35%)
Mayo Clinic-Backed NMTC Could Be Worth 3X This Year

For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery...

VTGN : 1.46 (-1.35%)
MRNS : 6.96 (-0.43%)
VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage

VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, and its wholly-owned...

VTGN : 1.46 (-1.35%)
This Morning's Technical Outlook on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration....

VKTX : 12.22 (-1.93%)
ZIOP : 3.40 (-3.13%)
VCEL : 12.10 (-2.02%)
VTGN : 1.46 (-1.35%)
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - April 10, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...

VTGN : 1.46 (-1.35%)
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - April 05, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...

VTGN : 1.46 (-1.35%)
VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - March 19, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other...

VTGN : 1.46 (-1.35%)
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration....

VKTX : 12.22 (-1.93%)
ZIOP : 3.40 (-3.13%)
VCEL : 12.10 (-2.02%)
VTGN : 1.46 (-1.35%)
VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101

SAN FRANCISCO, CA--(Marketwired - March 07, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central...

VTGN : 1.46 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More Share

Trade VTGN with:

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

2nd Resistance Point 1.51
1st Resistance Point 1.48
Last Price 1.46
1st Support Level 1.44
2nd Support Level 1.42

See More

52-Week High 2.65
Fibonacci 61.8% 1.90
Fibonacci 50% 1.67
Last Price 1.46
Fibonacci 38.2% 1.44
52-Week Low 0.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar